Francis Saigh, MD
Family Medicine · Norway, MINPI 1932274115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 63.2% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $38, 2.2 times the $17 reported in 2022. That places this record below the midpoint for family medicine clinicians in MI, where the typical reported total is $260.
Across 5 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$59
- Neurocrine Biosciences, Inc.$17
- Avanos Medical$17
What the payments were for
- Food & beverage$93100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $59 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Avanos Medical | 1 | $17 |
How this compares
$93 in reported general payments places this provider in the 25th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 11 | $74,848 |
| Invega SustennaPaliperidone Palmitate | 13 | $48,488 |
| XareltoRivaroxaban | 74 | $20,020 |
| EliquisApixaban | 53 | $19,156 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $10,189 |
| Aripiprazole | 14 | $6,828 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 19 | $5,978 |
| Atorvastatin Calcium | 191 | $5,288 |
| Gabapentin | 166 | $5,149 |
| Memantine Hcl | 67 | $4,876 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 218 | $4,514 |
| JanuviaSitagliptin Phosphate | 15 | $4,375 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 108 | $4,155 |
| Olanzapine | 20 | $4,139 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $3,812 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Norway
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.